RU2016143552A - Гуманизированные антитела к антигену Томсена-Фриденрайха - Google Patents
Гуманизированные антитела к антигену Томсена-Фриденрайха Download PDFInfo
- Publication number
- RU2016143552A RU2016143552A RU2016143552A RU2016143552A RU2016143552A RU 2016143552 A RU2016143552 A RU 2016143552A RU 2016143552 A RU2016143552 A RU 2016143552A RU 2016143552 A RU2016143552 A RU 2016143552A RU 2016143552 A RU2016143552 A RU 2016143552A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- mab
- sequence consisting
- fragment
- sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (31)
1. Частично гуманизированное моноклональное антитело (mAb) или его фрагмент, которые связываются со специфичностью с TF-Ag, при этом моноклональное антитело или его фрагмент содержат тяжелую цепь и легкую цепь, причем тяжелая цепь содержит последовательность, выбранную из группы, состоящей из:
a) последовательности, состоящей из:
EVQLVESGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGFISPNTDYTEYNQKFRDRVTMTADTSISTAYMELSRLRSDDTAVYYCARSFIGYNFDFWGQGTLVTVSS (SEQ ID NO: 7) (H1);
b) последовательности, состоящей из:
EVQLLESGAELKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGFISPNTDYTEYNQKFRDRVTLTADKSSSTAYMELSSLTSEDTAVYYCARSFIGYNFDFWGQGTTVTVSS (SEQ ID NO: 8) (Н2);
c) последовательности, состоящей из:
EVQLVESGAEVKKPGASVKVSCKASGYTFTTYWMHWVKQAPGQGLEWIGFISPNTDYTEYNQKFRDKATMTADTSISTAYMELSRLRSDDTAVYYCARSFIGYNFDFWGQGTTLTVSS (SEQ ID NO: 9) (Н3),
d) последовательности, состоящей из:
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGFISPNTDYTEYNQKFRDRVTITADKSTSTAYMELSSLRSEDTAVYYCARSFIGYNFDFWGQGTTVTVS (SEQ ID NO: 13) (Н2а);
e) последовательности, состоящей из:
EGQLLESGAELAKPGASVKMSCKASGYTFTTYWMHWVKKRPGQGLEWIGFISPNTDYTEYNQKFRDKATLTADKSSTTAYMQLSSLTSDDSAVYYCARSFIGYNFDFWGQGTTLTVSS (SEQ ID NO: 14) (Н3а); и
их комбинаций;
и при этом легкая цепь содержит последовательность, выбранную из группы, состоящей из:
d) последовательности, состоящей из:
DVVMTQSPLSLPVTLGQPASISCRSSQTIVYSNGNTYLEWFQQRPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 10) (L1);
e) последовательности, состоящей из:
DIVMTQTPLSLPVTLGQPASISCRSSQTIVYSNGNTYLEWFQQRPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 11) (L2);
f) последовательности, состоящей из:
DVVMTQSPLSLPVTLGQPASISCRSSQTIVYSNGNTYLEWYLQRPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 12) (L3);
g) последовательности, состоящей из:
DIVMTQSPLSLPVTPGEPASISCRSSQTIVYSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPFTFGSGTKVDIK (SEQ ID NO: 15) (L2a);
h) последовательности, состоящей из:
ELVMTQTPLSLPVNLGDQASISCRSSQTIVYSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEADDLGVYYCFQGSHVPFTFGSGTKLEIK (SEQ ID NO: 16) (L3a);
и их комбинаций.
2. mAb по п. 1, при этом mAb содержит константную область IgG человека.
3. mAb по п. 1, при этом mAb или его фрагмент конъюгирован с агентом, выбранным из группы, состоящей из химиотерапевтических лекарственных средств, токсинов и радиоактивных изотопов.
4. Способ профилактики и/или лечения рака у индивидуума, при этом рак содержит раковые клетки, экспрессирующие TF-Ag, причем способ включает стадию, на которой вводят индивидууму одно или более mAb или их фрагментов по п. 1, при этом рост, или выживание, или метастазирование, или их комбинация, раковых клеток у индивидуума ингибируется после введения.
5. Способ по п. 4, в котором mAb содержит константную область IgG человека.
6. Способ по п. 4, в котором mAb или его фрагмент конъюгирован с агентом, выбранным из группы, состоящей из химиотерапевтических лекарственных средств, токсинов и радиоактивных изотопов.
7. Фармацевтическая композиция, содержащая частично гуманизированное mAb или его фрагмент по п. 1.
8. Клеточная культура in vitro, при этом клетки в клеточной культуре экспрессируют частично гуманизированное mAb или его фрагмент по п. 1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461981240P | 2014-04-18 | 2014-04-18 | |
| US61/981,240 | 2014-04-18 | ||
| PCT/US2015/026595 WO2015161311A2 (en) | 2014-04-18 | 2015-04-20 | Humanized anti-tf-antigen antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016143552A true RU2016143552A (ru) | 2018-05-21 |
| RU2016143552A3 RU2016143552A3 (ru) | 2018-11-14 |
| RU2699717C2 RU2699717C2 (ru) | 2019-09-09 |
Family
ID=54324717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016143552A RU2699717C2 (ru) | 2014-04-18 | 2015-04-20 | Гуманизированные антитела к антигену Томсена-Фриденрайха |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11130821B2 (ru) |
| EP (2) | EP3797793A1 (ru) |
| JP (1) | JP6740135B2 (ru) |
| KR (1) | KR102413809B1 (ru) |
| CN (1) | CN106488774B (ru) |
| AU (1) | AU2015247358B2 (ru) |
| BR (1) | BR112016024214B8 (ru) |
| CA (1) | CA2943681A1 (ru) |
| ES (1) | ES2843546T3 (ru) |
| MX (2) | MX2016013686A (ru) |
| RU (1) | RU2699717C2 (ru) |
| WO (1) | WO2015161311A2 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118267470A (zh) | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| SG11202001401TA (en) * | 2017-09-22 | 2020-04-29 | Immunogen Inc | Separation of triple-light chain antibodies using cation exchange chromatography |
| US12060427B2 (en) * | 2018-03-28 | 2024-08-13 | Mitsubishi Tanabe Pharma Corporat | Drug conjugates of cMET monoclonal binding agents, and uses thereof |
| WO2019231957A1 (en) * | 2018-05-30 | 2019-12-05 | National Health Research Institutes | Anti-abeta antibodies and uses thereof |
| US20230071889A1 (en) | 2018-12-21 | 2023-03-09 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| BR112021011982A2 (pt) | 2018-12-21 | 2021-09-14 | Ose Immunotherapeutics | Anticorpo anti-humano-pd-1 humanizado |
| KR20210107062A (ko) | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 이작용성 항-PD-1/SIRPα 분자 |
| KR20210107058A (ko) | 2018-12-21 | 2021-08-31 | 오제 이뮈노테라프틱스 | 인간 pd-1에 대항하는 이작용성 분자 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005116652A2 (en) * | 2004-04-16 | 2005-12-08 | Vanderbilt University | Method for in vitro diagnosis of sjörgen’s syndrome and lupus |
| EP1789027B1 (en) * | 2004-07-26 | 2013-09-04 | The Research Foundation Of State University Of New York | Therapeutic use of anti-tf-antigen antibody |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| WO2007109749A2 (en) * | 2006-03-21 | 2007-09-27 | Wyeth | Methods for preventing and treating amyloidogenic diseases |
| EP2161031A1 (en) * | 2008-09-05 | 2010-03-10 | SuppreMol GmbH | Fc gamma receptor for the treatment of B cell mediated multiple sclerosis |
| LT2488551T (lt) * | 2009-10-16 | 2018-10-25 | Progastrine Et Cancers S.A R.L. | Monokloniniai antikūnai prieš progastriną ir jų panaudojimas |
| EP2347769A1 (en) * | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| WO2012143524A2 (en) * | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| CN104080909A (zh) * | 2011-11-30 | 2014-10-01 | 中外制药株式会社 | 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物 |
| CN102796144A (zh) * | 2012-08-22 | 2012-11-28 | 山东大学 | Tf抗原及其类似物、和其化学酶法合成方法及其应用 |
| US10023651B2 (en) * | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
-
2015
- 2015-04-20 WO PCT/US2015/026595 patent/WO2015161311A2/en active Application Filing
- 2015-04-20 EP EP20197413.6A patent/EP3797793A1/en active Pending
- 2015-04-20 MX MX2016013686A patent/MX2016013686A/es unknown
- 2015-04-20 EP EP15780559.9A patent/EP3131581B1/en active Active
- 2015-04-20 CA CA2943681A patent/CA2943681A1/en active Pending
- 2015-04-20 ES ES15780559T patent/ES2843546T3/es active Active
- 2015-04-20 CN CN201580027114.8A patent/CN106488774B/zh active Active
- 2015-04-20 RU RU2016143552A patent/RU2699717C2/ru active
- 2015-04-20 AU AU2015247358A patent/AU2015247358B2/en active Active
- 2015-04-20 BR BR112016024214A patent/BR112016024214B8/pt active IP Right Grant
- 2015-04-20 KR KR1020167031646A patent/KR102413809B1/ko active IP Right Grant
- 2015-04-20 JP JP2016558558A patent/JP6740135B2/ja active Active
-
2016
- 2016-10-18 MX MX2021000439A patent/MX2021000439A/es unknown
-
2018
- 2018-05-10 US US15/976,500 patent/US11130821B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11130821B2 (en) | 2021-09-28 |
| AU2015247358A1 (en) | 2016-11-10 |
| EP3131581A2 (en) | 2017-02-22 |
| EP3797793A1 (en) | 2021-03-31 |
| CN106488774A (zh) | 2017-03-08 |
| AU2015247358B2 (en) | 2020-02-27 |
| WO2015161311A2 (en) | 2015-10-22 |
| CA2943681A1 (en) | 2015-10-22 |
| ES2843546T3 (es) | 2021-07-19 |
| JP2017518260A (ja) | 2017-07-06 |
| KR102413809B1 (ko) | 2022-06-28 |
| BR112016024214A2 (pt) | 2018-01-23 |
| WO2015161311A3 (en) | 2015-12-10 |
| EP3131581A4 (en) | 2018-02-21 |
| KR20170010356A (ko) | 2017-01-31 |
| EP3131581B1 (en) | 2020-09-23 |
| RU2016143552A3 (ru) | 2018-11-14 |
| JP6740135B2 (ja) | 2020-08-12 |
| MX2016013686A (es) | 2017-03-31 |
| RU2699717C2 (ru) | 2019-09-09 |
| US20180258182A1 (en) | 2018-09-13 |
| MX2021000439A (es) | 2021-03-25 |
| BR112016024214B8 (pt) | 2023-12-26 |
| BR112016024214B1 (pt) | 2023-11-14 |
| CN106488774B (zh) | 2019-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016143552A (ru) | Гуманизированные антитела к антигену Томсена-Фриденрайха | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| HRP20171315T1 (hr) | Optimizacija humanih antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2017518260A5 (ru) | ||
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| PE20141908A1 (es) | Anticuerpos cd47 y metodos de uso los mismos | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
| EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| MX2018012473A (es) | Agentes que reconocen el epitopo de clever-1 y usos de los mismos. | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител |